G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia
Alireza Eghtedar,Gautam Borthakur,Farhad Ravandi,Elias Jabbour,Jorge E. Cortes,Sherry Pierce,Hagop M. Kantarjian,Guillermo Garcia-Manero +7 more
TL;DR: The natural history of patients with t(16:16)(p13;q22) is similar to that of classic patients with inv16 AML and therefore should be treated similarly.
Journal ArticleDOI
Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification
Patrick K. Reville,Koji Sasaki,Hagop M. Kantarjian,Naval Daver,Musa Yilmaz,Courtney D. DiNardo,Nicholas J. Short,Gautam Borthakur,Naveen Pemmaraju,Rohtesh S. Mehta,Sherry Pierce,Sergej Konoplev,Joseph D. Khoury,Guillermo Garcia-Manero,Marina Konopleva,Elias Jabbour,Farhad Ravandi,Tapan M. Kadia +17 more
TL;DR: Analysis of a consecutive cohort of newly diagnosed patients with AML treated at a large academic medical center from January 2012 to January 2020 shows that FLT3‐ITD high AR with NPM1 wild‐type have significantly improved survival compared with other European LeukemiaNet (ELN) adverse risk disease.
Journal ArticleDOI
Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Tapan M. Kadia,Jorge E. Cortes,Marina Konopleva,Gautam Borthakur,Naveen Pemmaraju,Naval Daver,Guillermo Montalban Bravo,Ghayas C. Issa,Kiran Naqvi,Nicholas J. Short,Courtney D. DiNardo,Kapil N. Bhalla,Elias Jabbour,Koichi Takahashi,Koji Sasaki,Steven M. Kornblau,Rashmi Malla,Sherry Pierce,Xuemei Wang,Zeev Estrov,Michael Andreeff,Guillermo Garcia-Manero,Farhad Ravandi,Hagop M. Kantarjian +23 more
TL;DR: A phase II clinical trial studying the combination of venetoclax with CLAD/LDAC alternating with 5-azacytidine (AZA) in older or unfit patients with newly diagnosed AML, producing high rates of MRD negative remission and meaningful blood count.
Journal ArticleDOI
Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome.
Mar Mallo,Elisa Luño,Carmen Sanzo,José Cervera,Detlef Haase,Julie Schanz,Guillermo Garcia-Manero,Consuelo del Cañizo,Guillermo Sanz,Francesc Solé +9 more
TL;DR: The clone size has been postulated as a prognostic factor in myelodysplastic syndromes (MDS) though it has not been studied systematically, and the bad prognosis of -7/7q- was independent of the clone size.
Journal ArticleDOI
Validation of a Prognostic Model and the Impact of SF3B1, DNMT3A, and Other Mutations in 289 Genetically Characterized Lower Risk MDS Patient Samples
Rafael Bejar,Kristen E. Stevenson,Bennett Caughey,Omar Abdel-Wahab,Naomi Galili,Guillermo Garcia-Manero,Hagop M. Kantarjian,Azra Raza,David P. Steensma,Ross L. Levine,Donna Neuberg,Benjamin L. Ebert +11 more
TL;DR: This study validates the LR-PSS ability to identify higher risk MDS patients among those with lower IPSS risk and demonstrates that point mutations are common in this cohort, associate with specific clinical features, and independently provide both favorable and adverse prognostic information.